Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 6/20 | 0.47 |
| ▸ | IL4I1 | Q96RQ9 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30948316 | 0.98 | TP53 (0.47) | TP53IL4I1LMNARXFP1POLB | |
| SCHEMBL30947906 | 0.87 | TP53 (0.48) | TP53IL4I1LMNARXFP1 | |
| SCHEMBL27163155 | 0.83 | TP53 (0.54) | TP53IL4I1LMNA | |
| SCHEMBL30948055 | 0.83 | TP53 (0.54) | TP53IL4I1LMNARXFP1POLB | |
| SCHEMBL30948268 | 0.82 | TP53 (0.44) | TP53IL4I1LMNARXFP1 | |
| SCHEMBL30947946 | 0.81 | CHRM1 (0.51) | TP53IL4I1LMNARXFP1POLB | |
| SCHEMBL30948046 | 0.81 | IL4I1 (0.58) | TP53IL4I1LMNARXFP1POLB | |
| SCHEMBL30948244 | 0.81 | TP53 (0.54) | TP53IL4I1LMNARXFP1POLB | |
| SCHEMBL30948165 | 0.80 | IL4I1 (0.47) | TP53IL4I1LMNARXFP1POLB | |
| SCHEMBL30045586 | 0.80 | CACNA1H (0.42) | TP53IL4I1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-25 | — | — | US | disclosed |
| EP-4329889-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022227015-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022232333-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | TP53 1444/4885IL4I1 1/4885LMNA 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.